Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
Sign Up to like & getrecommendations! Published in 2017 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-017-1784-1
Abstract: BackgroundEverolimus with exemestane has shown promising activity in patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant advanced breast cancer. It is necessary, therefore, to characterize the safety profile of this new combination in the real-world clinical setting… read more here.
Keywords: trial; positive her2; safety; breast cancer ... See more keywords